GFAP and Alzheimer disease: In more detail, using isoform‐specific antibodies may hold promise for staging AD in terms of inflammation; the shortened rod isoforms (GFAP+1) are associated with disease progression as GFAP+1 positive astrocytes have been shown to increase in number over the course of AD (Kamphuis et al., 2014).